Cargando…

EGF Potentiation of VEGF Production Is Cell Density Dependent in H292 EGFR Wild Type NSCLC Cell Line

Non-small cell lung cancer (NSCLC) affects millions of patients each year worldwide. Existing therapies include epidermal growth factor receptor (EGFR) inhibition using small molecules or antibodies with good efficacy. Unfortunately, intrinsic and acquired resistance to EGFR therapy remains a persis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ranayhossaini, Daniel J., Lu, Jin, Mabus, John, Gervais, Alexis, Lingham, Russell B., Fursov, Natalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227184/ https://www.ncbi.nlm.nih.gov/pubmed/25272226 http://dx.doi.org/10.3390/ijms151017686

Ejemplares similares

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
por: Zhou, Xin, et al.
Publicado: (2021)

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
por: Hafner, Susanne
Publicado: (2021)

EGF regulation of proximal tubule cell proliferation and VEGF‐A secretion
por: Zepeda‐Orozco, Diana, et al.
Publicado: (2017)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.
por: Kirk, J., et al.
Publicado: (1994)

ZNF292 suppresses proliferation of ESCC cells through ZNF292/SKP2/P27 signaling axis
por: Gong, Wei, et al.
Publicado: (2021)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

NCI-H292 as an alternative cell line for the isolation and propagation of the human paramyxoviruses
por: Castells, Empar, et al.
Publicado: (1990)

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
por: Fang, Shencun, et al.
Publicado: (2017)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

Poster Sessions 292 - 465
Publicado: (2003)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

PKG II Inhibits EGF/EGFR-Induced Migration of Gastric Cancer Cells
por: Jiang, Lu, et al.
Publicado: (2013)

Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report
por: Wu, Yuan-Peng, et al.
Publicado: (2019)

CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells
por: Deng, Wenjie, et al.
Publicado: (2016)

Critical roles for EGFR and EGFR–HER2 clusters in EGF binding of SW620 human carcinoma cells
por: Wollman, Adam J. M., et al.
Publicado: (2022)

Genetic Variants of EGF and VEGF Predict Prognosis of Patients with Advanced Esophageal Squamous Cell Carcinoma
por: Yang, Pei-Wen, et al.
Publicado: (2014)

EGF Functionalized Polymer-Coated Gold Nanoparticles Promote EGF Photostability and EGFR Internalization for Photothermal Therapy
por: Silva, Catarina Oliveira, et al.
Publicado: (2016)

Health Tract, No. 292: Life’s Battle
Publicado: (1867)

Excess HB-EGF, which promotes VEGF signaling, leads to hydrocephalus
por: Shim, Joon W., et al.
Publicado: (2016)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer
por: Di Donato, Marzia, et al.
Publicado: (2023)

EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation
por: Yao, Wenfang, et al.
Publicado: (2012)

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
por: Volta, Francesco, et al.
Publicado: (2023)

VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis
por: Butt, Christopher, et al.
Publicado: (2007)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
por: Zhou, Fei, et al.
Publicado: (2015)

Prognostic value of CYFRA 21 − 1 and Ki67 in advanced NSCLC patients with wild-type EGFR
por: Li, Tao, et al.
Publicado: (2023)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

Development and Evaluation of (18)F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC
por: Song, Yan, et al.
Publicado: (2017)

Enhanced nuclear localization of YAP1‐2 contributes to EGF‐induced EMT in NSCLC
por: Guo, Qiang, et al.
Publicado: (2022)

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023)

The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment
por: Huang, Peixin, et al.
Publicado: (2014)

Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation
por: Zheng, Jianchao, et al.
Publicado: (2017)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
por: Sueangoen, Natthaporn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_30j9kecdjfmoh9hou8igsmdmhj